Your Messages Inbox
Your Article Summary
See Latest ArticlesGilead Sciences Announces Agreement With Tibotec Pharmaceuticals to Develop and Commercialize New Fixed-Dose Combination of Truvada and TMC278
Gilead, 07/17/09
Gilead Sciences, Inc. announced that it has entered into a license and collaboration agreement with Tibotec Pharmaceuticals for the development and commercialization of a new once–daily fixed–dose antiretroviral regimen containing Gilead’s Truvada (emtricitabine and tenofovir disoproxil fumarate) and Tibotec’s investigational non–nucleoside reverse transcriptase inhibitor (NNRTI) TMC278 (rilpivirine hydrochloride, 25 mg) for treatment–naive HIV–infected individuals. Fixed–dose combinations contain multiple medicines formulated into one tablet and help to simplify HIV therapy.
Related Articles
Evaluation of Dural Arteriovenous Fistulas with 4D Contrast-Enhanced MR Angiography at 3T
American Journal of Neuroradiology, 10/30/09
Relevance Score: 87%
Cephalon Signs Option Agreement to Acquire BioAssets Development Corporation
Cephalon, 10/27/09
Relevance Score: 87%
Intra-examiner repeatability and agreement in accommodative response measurements
Ophthalmic and Physiological Optics, 10/27/09
Relevance Score: 87%
Interobserver variation in the reporting of local peritoneal involvement and extramural venous invasion in colonic cancer
Histopathology, 10/15/09
Relevance Score: 85%
Sanofi-aventis and US biopharmaceutical company Micromet sign global collaboration and license agreement for new solid tumor BiTE antibody
Sanofi-aventis, 10/30/09
Relevance Score: 84%
Today in M&A/Partnerships...keeping you current
Receive free subspecialty "5-minute updates" via email
Amylin Pharmaceuticals and Takeda Enter into Worldwide Agreement to Co-Develop and Commercialize Compounds for Obesity
Takeda Pharmaceuticals North America, 12/08/09
Cerner Enters R&D Pact with University
HealthDataManagement, 12/08/09
Allos Therapeutics Announces an Agreement with Idis for a Named Patient Program for FOLOTYN (pralatrexate injection)
Allos Therapeutics, 12/07/09
Article Search
Sponsor